COPENHAGEN, Denmark, July 19, 2022 – Bavarian Nordic A/S (OMX:BAVA) announced today that a non-disclosed country has ordered an additional 1.5 million doses of IMVANEX®, a non-replicating smallpox vaccine. While deliveries under this contract will start in 2022, the majority of the doses will be delivered during 2023 and as such this order has no impact on the financial guidance for this year.
Read more at globenewswire.comBavarian Nordic Secures Significant European Smallpox/Monkeypox Vaccine Order for 2023
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here